Profil
Mammen P.
Mammen formerly worked at Vical, Inc., as Vice President-Clinical Vaccines from 2012 to 2017, Inovio Pharmaceuticals, Inc., as Senior Vice President-Clinical Development from 2020 to 2022, and Walter Reed Army Institute of Research, as Principal.
Dr. Mammen received his doctorate degree from The Pennsylvania State University and undergraduate degree from Williams College.
Anciens postes connus de Mammen P. Mammen
| Sociétés | Poste | Fin |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2022 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | - |
Formation de Mammen P. Mammen
| The Pennsylvania State University | Doctorate Degree |
| Williams College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
| Walter Reed Army Institute of Research |
